|
04 Dec 2019 |
Censa Pharmaceuticals Announces CNSA-001 Met Primary and Secondary Endpoints in Phase 2 Trial in Patients with PKU
|
|
04 Dec 2019 |
Aerie Pharmaceuticals Submits Marketing Authorisation Application for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% in Europe
|
|
04 Dec 2019 |
Aldeyra Therapeutics Announces Positive Top-Line Results from Part 1 of Adaptive Phase 3 RENEW Trial in Dry Eye Disease
|
|
03 Dec 2019 |
Mission and AbbVie’s Collaboration in Alzheimer’s and Parkinson’s Diseases Reaches Milestone
|
|
02 Dec 2019 |
European Medicines Agency Accepts for Review Marketing Authorization Application for Amarin’s Icosapent Ethyl (Vascepa®) for Reduction of Cardiovascular Risk in High-Risk Patients, as Reflected in REDUCE-IT® Study
|
|
02 Dec 2019 |
Sensorion Announces Results From SENS-111 Phase 2b Trial in Acute Unilateral Vestibulopathy
|
|
02 Dec 2019 |
Concert Pharmaceuticals Initiates CTP-692 Phase 2 Trial in Schizophrenia
|
|
02 Dec 2019 |
Phathom Pharmaceuticals Announces Initiation of Pivotal Phase 3 Clinical Trial for Vonoprazan in Erosive Esophagitis
|
|
27 Nov 2019 |
Incyte Announces Acceptance and Priority Review of NDA for Pemigatinib as a Treatment for Patients with Cholangiocarcinoma
|
|
27 Nov 2019 |
CymaBay Therapeutics Halts Clinical Development of Seladelpar
|
|
26 Nov 2019 |
Mitsubishi Tanabe Pharma America Announces Initiation of Phase 3 Study Evaluating Investigational Oral Formulation of Edaravone for ALS
|
|
26 Nov 2019 |
INHIBITOR Therapeutics Submits Investigational New Drug Application for Treatment of Patients with Late-Stage Prostate Cancer
|
|
26 Nov 2019 |
FDA Approves Oxbryta™ (Voxelotor), the First Medicine Specifically Targeting the Root Cause of Sickle Cell Disease
|
|
26 Nov 2019 |
EpicentRx Announces Positive Results From Phase 1 Trial of RRx-001 as First-line Treatment in Newly Diagnosed Glioblastoma
|
|
26 Nov 2019 |
Verastem Oncology Announces Submission of a Marketing Authorization Application to the European Medicines Agency for COPIKTRA® (duvelisib)
|
|
26 Nov 2019 |
ACADIA Pharmaceuticals Announces Positive Top-line Results from ADVANCE Trial of Pimavanserin as Treatment for Negative Symptoms of Schizophrenia
|
|
26 Nov 2019 |
VFMCRP and ChemoCentryx Announce Positive Topline Data From Pivotal Phase-III ADVOCATE Trial Demonstrating Avacopan’s Superiority Over Standard of Care in ANCA Associated Vasculitis
|
|
25 Nov 2019 |
FDA Grants Priority Review to Genentech’s Risdiplam for Spinal Muscular Atrophy
|
|
24 Nov 2019 |
Dosing of first patient in phase 3 pivotal study of sovateltide (PMZ-1620), a first-in-class investigational product, for acute cerebral ischemic stroke
|
|
23 Nov 2019 |
Oyster Point Pharma Announces Positive Top-Line Results From the Phase 1 “ZEN” Study of Its Lead Nicotinic Agonist Nasal Spray in Development for the Treatment of Dry Eye Disease
|
|
22 Nov 2019 |
Biogen Presents Data Demonstrating Improved Gastrointestinal Tolerability With VUMERITY™ (diroximel fumarate) Compared to TECFIDERA® (dimethyl fumarate)
|
|
22 Nov 2019 |
FDA Approves XCOPRI® (cenobamate tablets), an Anti-Epileptic Drug (AED) from SK Biopharmaceuticals, Co., Ltd., and U.S. Subsidiary SK Life Science, Inc.
|
|
22 Nov 2019 |
Calquence approved in the US for adult patients with chronic lymphocytic leukaemia
|
|
21 Nov 2019 |
Tonix Pharmaceuticals Announces Initiation of the Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia
|
|
21 Nov 2019 |
Initiation of a Phase 2 Multicenter Study of 18F-APN-1607, a Novel Diagnostic PET Imaging Tracer for the Characterization of Tau Burden in Alzheimer's Disease
|
